Which has stronger earnings & valuation, CGEM or VKTX?

Viking Therapeutics is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cullinan Therapeutics N/A N/A -$219.88M -$3.36 N/A Viking Therapeutics N/A N/A -$359.64M -$4.14 N/A

Is CGEM or VKTX more profitable?

Cullinan Therapeutics' return on equity of -51.45% beat Viking Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cullinan Therapeutics N/A -51.45% -47.64% Viking Therapeutics N/A -71.31% -65.35%

Does the media favor CGEM or VKTX?

In the previous week, Viking Therapeutics had 8 more articles in the media than Cullinan Therapeutics. MarketBeat recorded 11 mentions for Viking Therapeutics and 3 mentions for Cullinan Therapeutics. Cullinan Therapeutics' average media sentiment score of 0.34 beat Viking Therapeutics' score of 0.28 indicating that Cullinan Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cullinan Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Viking Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to CGEM or ACAD?

In the previous week, ACADIA Pharmaceuticals had 3 more articles in the media than Cullinan Therapeutics. MarketBeat recorded 6 mentions for ACADIA Pharmaceuticals and 3 mentions for Cullinan Therapeutics. ACADIA Pharmaceuticals' average media sentiment score of 0.83 beat Cullinan Therapeutics' score of 0.34 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cullinan Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ACADIA Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, CGEM or EWTX?

Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cullinan Therapeutics N/A N/A -$219.88M -$3.36 N/A Edgewise Therapeutics N/A N/A -$167.79M -$1.66 N/A

Is CGEM or EWTX more profitable?

Edgewise Therapeutics' return on equity of -32.55% beat Cullinan Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cullinan Therapeutics N/A -51.45% -47.64% Edgewise Therapeutics N/A -32.55% -31.04%

Does the media favor CGEM or EWTX?

In the previous week, Cullinan Therapeutics and Cullinan Therapeutics both had 3 articles in the media. Edgewise Therapeutics' average media sentiment score of 0.66 beat Cullinan Therapeutics' score of 0.34 indicating that Edgewise Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cullinan Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Edgewise Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is CGEM or TNGX more profitable?

Tango Therapeutics' return on equity of -41.54% beat Cullinan Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cullinan Therapeutics N/A -51.45% -47.64% Tango Therapeutics N/A -41.54% -33.44%

Does the media favor CGEM or TNGX?

In the previous week, Tango Therapeutics had 2 more articles in the media than Cullinan Therapeutics. MarketBeat recorded 5 mentions for Tango Therapeutics and 3 mentions for Cullinan Therapeutics. Tango Therapeutics' average media sentiment score of 0.35 beat Cullinan Therapeutics' score of 0.34 indicating that Tango Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cullinan Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tango Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to NAMS or CGEM?

In the previous week, NewAmsterdam Pharma and NewAmsterdam Pharma both had 3 articles in the media. NewAmsterdam Pharma's average media sentiment score of 0.51 beat Cullinan Therapeutics' score of 0.34 indicating that NewAmsterdam Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NewAmsterdam Pharma 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cullinan Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Cullinan Therapeutics (CGEM) Competitors

$17.50 -0.19 (-1.07%)

Closing price 07/20/2026 04:00 PM Eastern

Extended Trading

$17.63 +0.13 (+0.75%)

As of 05:25 AM Eastern

Compare

CGEM vs. VKTX, ACAD, EWTX, TNGX, and NAMS

Should you buy Cullinan Therapeutics stock or one of its competitors? MarketBeat compares Cullinan Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cullinan Therapeutics include Viking Therapeutics (VKTX), ACADIA Pharmaceuticals (ACAD), Edgewise Therapeutics (EWTX), Tango Therapeutics (TNGX), and NewAmsterdam Pharma (NAMS). These companies are all part of the "pharmaceutical products" industry.

How does Cullinan Therapeutics compare to Viking Therapeutics?

Cullinan Therapeutics (NASDAQ:CGEM) and Viking Therapeutics (NASDAQ:VKTX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability.

In the previous week, Viking Therapeutics had 8 more articles in the media than Cullinan Therapeutics. MarketBeat recorded 11 mentions for Viking Therapeutics and 3 mentions for Cullinan Therapeutics. Cullinan Therapeutics' average media sentiment score of 0.34 beat Viking Therapeutics' score of 0.28 indicating that Cullinan Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cullinan Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Viking Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

86.3% of Cullinan Therapeutics shares are owned by institutional investors. Comparatively, 76.0% of Viking Therapeutics shares are owned by institutional investors. 8.6% of Cullinan Therapeutics shares are owned by insiders. Comparatively, 5.3% of Viking Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Cullinan Therapeutics presently has a consensus price target of $32.00, suggesting a potential upside of 82.86%. Viking Therapeutics has a consensus price target of $93.60, suggesting a potential upside of 157.28%. Given Viking Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Viking Therapeutics is more favorable than Cullinan Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Viking Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.79

Cullinan Therapeutics' return on equity of -51.45% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cullinan Therapeutics	N/A	-51.45%	-47.64%
Viking Therapeutics	N/A	-71.31%	-65.35%

Cullinan Therapeutics has a beta of -0.01, suggesting that its share price is 101% less volatile than the broader market. Comparatively, Viking Therapeutics has a beta of 0.66, suggesting that its share price is 34% less volatile than the broader market.

Viking Therapeutics is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.36	N/A
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.14	N/A

Summary

Cullinan Therapeutics beats Viking Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Cullinan Therapeutics compare to ACADIA Pharmaceuticals?

Cullinan Therapeutics (NASDAQ:CGEM) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, risk, earnings and media sentiment.

In the previous week, ACADIA Pharmaceuticals had 3 more articles in the media than Cullinan Therapeutics. MarketBeat recorded 6 mentions for ACADIA Pharmaceuticals and 3 mentions for Cullinan Therapeutics. ACADIA Pharmaceuticals' average media sentiment score of 0.83 beat Cullinan Therapeutics' score of 0.34 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cullinan Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ACADIA Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

86.3% of Cullinan Therapeutics shares are owned by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. 8.6% of Cullinan Therapeutics shares are owned by company insiders. Comparatively, 26.2% of ACADIA Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

ACADIA Pharmaceuticals has higher revenue and earnings than Cullinan Therapeutics. Cullinan Therapeutics is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.36	N/A
ACADIA Pharmaceuticals	$1.07B	4.01	$391M	$2.20	11.40

ACADIA Pharmaceuticals has a net margin of 34.30% compared to Cullinan Therapeutics' net margin of 0.00%. ACADIA Pharmaceuticals' return on equity of 9.61% beat Cullinan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cullinan Therapeutics	N/A	-51.45%	-47.64%
ACADIA Pharmaceuticals	34.30%	9.61%	7.07%

Cullinan Therapeutics has a beta of -0.01, indicating that its share price is 101% less volatile than the broader market. Comparatively, ACADIA Pharmaceuticals has a beta of 0.8, indicating that its share price is 20% less volatile than the broader market.

Cullinan Therapeutics presently has a consensus target price of $32.00, suggesting a potential upside of 82.86%. ACADIA Pharmaceuticals has a consensus target price of $32.94, suggesting a potential upside of 31.29%. Given Cullinan Therapeutics' higher probable upside, research analysts plainly believe Cullinan Therapeutics is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
ACADIA Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.65

Summary

ACADIA Pharmaceuticals beats Cullinan Therapeutics on 14 of the 15 factors compared between the two stocks.

How does Cullinan Therapeutics compare to Edgewise Therapeutics?

Cullinan Therapeutics (NASDAQ:CGEM) and Edgewise Therapeutics (NASDAQ:EWTX) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability.

Edgewise Therapeutics' return on equity of -32.55% beat Cullinan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cullinan Therapeutics	N/A	-51.45%	-47.64%
Edgewise Therapeutics	N/A	-32.55%	-31.04%

Cullinan Therapeutics presently has a consensus price target of $32.00, suggesting a potential upside of 82.86%. Edgewise Therapeutics has a consensus price target of $48.75, suggesting a potential upside of 25.61%. Given Cullinan Therapeutics' higher probable upside, research analysts plainly believe Cullinan Therapeutics is more favorable than Edgewise Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

In the previous week, Cullinan Therapeutics and Cullinan Therapeutics both had 3 articles in the media. Edgewise Therapeutics' average media sentiment score of 0.66 beat Cullinan Therapeutics' score of 0.34 indicating that Edgewise Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cullinan Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Edgewise Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

86.3% of Cullinan Therapeutics shares are owned by institutional investors. 8.6% of Cullinan Therapeutics shares are owned by insiders. Comparatively, 21.3% of Edgewise Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Cullinan Therapeutics has a beta of -0.01, suggesting that its stock price is 101% less volatile than the broader market. Comparatively, Edgewise Therapeutics has a beta of 0.27, suggesting that its stock price is 73% less volatile than the broader market.

Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.36	N/A
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.66	N/A

Summary

Edgewise Therapeutics beats Cullinan Therapeutics on 10 of the 13 factors compared between the two stocks.

How does Cullinan Therapeutics compare to Tango Therapeutics?

Cullinan Therapeutics (NASDAQ:CGEM) and Tango Therapeutics (NASDAQ:TNGX) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, profitability, risk, institutional ownership, dividends, media sentiment, valuation and earnings.

In the previous week, Tango Therapeutics had 2 more articles in the media than Cullinan Therapeutics. MarketBeat recorded 5 mentions for Tango Therapeutics and 3 mentions for Cullinan Therapeutics. Tango Therapeutics' average media sentiment score of 0.35 beat Cullinan Therapeutics' score of 0.34 indicating that Tango Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cullinan Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tango Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cullinan Therapeutics presently has a consensus target price of $32.00, suggesting a potential upside of 82.86%. Tango Therapeutics has a consensus target price of $42.15, suggesting a potential upside of 53.06%. Given Cullinan Therapeutics' higher possible upside, research analysts clearly believe Cullinan Therapeutics is more favorable than Tango Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

Tango Therapeutics has higher revenue and earnings than Cullinan Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.36	N/A
Tango Therapeutics	$62.38M	63.86	-$101.59M	-$0.83	N/A

86.3% of Cullinan Therapeutics shares are held by institutional investors. Comparatively, 79.0% of Tango Therapeutics shares are held by institutional investors. 8.6% of Cullinan Therapeutics shares are held by company insiders. Comparatively, 6.5% of Tango Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Tango Therapeutics' return on equity of -41.54% beat Cullinan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cullinan Therapeutics	N/A	-51.45%	-47.64%
Tango Therapeutics	N/A	-41.54%	-33.44%

Cullinan Therapeutics has a beta of -0.01, meaning that its stock price is 101% less volatile than the broader market. Comparatively, Tango Therapeutics has a beta of 1.12, meaning that its stock price is 12% more volatile than the broader market.

Summary

Tango Therapeutics beats Cullinan Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Cullinan Therapeutics compare to NewAmsterdam Pharma?

NewAmsterdam Pharma (NASDAQ:NAMS) and Cullinan Therapeutics (NASDAQ:CGEM) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment, risk and earnings.

NewAmsterdam Pharma has higher revenue and earnings than Cullinan Therapeutics. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NewAmsterdam Pharma	$22.50M	154.15	-$203.82M	-$1.79	N/A
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.36	N/A

89.9% of NewAmsterdam Pharma shares are held by institutional investors. Comparatively, 86.3% of Cullinan Therapeutics shares are held by institutional investors. 12.7% of NewAmsterdam Pharma shares are held by company insiders. Comparatively, 8.6% of Cullinan Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Cullinan Therapeutics has a net margin of 0.00% compared to NewAmsterdam Pharma's net margin of -943.23%. NewAmsterdam Pharma's return on equity of -26.49% beat Cullinan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NewAmsterdam Pharma	-943.23%	-26.49%	-24.37%
Cullinan Therapeutics	N/A	-51.45%	-47.64%

NewAmsterdam Pharma currently has a consensus price target of $49.42, suggesting a potential upside of 66.55%. Cullinan Therapeutics has a consensus price target of $32.00, suggesting a potential upside of 82.86%. Given Cullinan Therapeutics' higher probable upside, analysts clearly believe Cullinan Therapeutics is more favorable than NewAmsterdam Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

NewAmsterdam Pharma has a beta of 0.08, suggesting that its share price is 92% less volatile than the broader market. Comparatively, Cullinan Therapeutics has a beta of -0.01, suggesting that its share price is 101% less volatile than the broader market.

In the previous week, NewAmsterdam Pharma and NewAmsterdam Pharma both had 3 articles in the media. NewAmsterdam Pharma's average media sentiment score of 0.51 beat Cullinan Therapeutics' score of 0.34 indicating that NewAmsterdam Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NewAmsterdam Pharma	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cullinan Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

NewAmsterdam Pharma beats Cullinan Therapeutics on 12 of the 15 factors compared between the two stocks.

Get Cullinan Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CGEM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CGEM vs. The Competition

Export

Metric	Cullinan Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.09B	$3.69B	$6.89B	$12.28B
Dividend Yield	N/A	2.16%	2.67%	9.39%
P/E Ratio	-5.21	20.49	27.07	23.94
Price / Sales	N/A	300.33	515.91	90.33
Price / Cash	N/A	60.31	26.68	47.25
Price / Book	2.53	7.92	10.43	6.14
Net Income	-$219.88M	$23.81M	$3.60B	$331.74M
7 Day Performance	-1.52%	-1.09%	-1.20%	-1.82%
1 Month Performance	16.43%	2.56%	1.12%	-1.45%
1 Year Performance	132.71%	42.16%	23.66%	16.32%

Cullinan Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CGEM Cullinan Therapeutics	2.4966 of 5 stars	$17.50 -1.1%	$32.00 +82.9%	+132.4%	$1.09B	N/A	N/A	30
VKTX Viking Therapeutics	3.1072 of 5 stars	$38.01 -0.3%	$93.60 +146.3%	+13.7%	$4.41B	N/A	N/A	20
ACAD ACADIA Pharmaceuticals	4.7931 of 5 stars	$25.36 -0.6%	$32.94 +29.9%	+11.2%	$4.34B	$1.07B	11.51	510
EWTX Edgewise Therapeutics	2.9623 of 5 stars	$39.88 -3.4%	$47.92 +20.1%	+186.6%	$4.28B	N/A	N/A	60	Analyst Forecast
TNGX Tango Therapeutics	2.5351 of 5 stars	$29.15 +2.8%	$41.50 +42.4%	+306.8%	$4.22B	$62.38M	N/A	90

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CGEM) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cullinan Therapeutics (CGEM) Competitors

CGEM vs. VKTX, ACAD, EWTX, TNGX, and NAMS

How does Cullinan Therapeutics compare to Viking Therapeutics?

Summary

How does Cullinan Therapeutics compare to ACADIA Pharmaceuticals?

Summary

How does Cullinan Therapeutics compare to Edgewise Therapeutics?

Summary

How does Cullinan Therapeutics compare to Tango Therapeutics?

Summary

How does Cullinan Therapeutics compare to NewAmsterdam Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGEM vs. The Competition

Cullinan Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cullinan Therapeutics (CGEM) Competitors

CGEM vs. VKTX, ACAD, EWTX, TNGX, and NAMS

How does Cullinan Therapeutics compare to Viking Therapeutics?

Does the media favor CGEM or VKTX?

Do institutionals and insiders have more ownership in CGEM or VKTX?

Do analysts prefer CGEM or VKTX?

Is CGEM or VKTX more profitable?

Which has more risk & volatility, CGEM or VKTX?

Which has stronger earnings & valuation, CGEM or VKTX?

Summary

How does Cullinan Therapeutics compare to ACADIA Pharmaceuticals?

Does the media refer more to CGEM or ACAD?

Do insiders and institutionals hold more shares of CGEM or ACAD?

Which has better earnings & valuation, CGEM or ACAD?

Is CGEM or ACAD more profitable?

Which has more risk & volatility, CGEM or ACAD?

Do analysts rate CGEM or ACAD?

Summary

How does Cullinan Therapeutics compare to Edgewise Therapeutics?

Is CGEM or EWTX more profitable?

Do analysts prefer CGEM or EWTX?

Does the media favor CGEM or EWTX?

Do insiders & institutionals have more ownership in CGEM or EWTX?

Which has more volatility and risk, CGEM or EWTX?

Which has higher earnings and valuation, CGEM or EWTX?

Summary

How does Cullinan Therapeutics compare to Tango Therapeutics?

Does the media favor CGEM or TNGX?

Do analysts recommend CGEM or TNGX?

Which has higher valuation & earnings, CGEM or TNGX?

Do insiders and institutionals have more ownership in CGEM or TNGX?

Is CGEM or TNGX more profitable?

Which has more volatility and risk, CGEM or TNGX?

Summary

How does Cullinan Therapeutics compare to NewAmsterdam Pharma?

Which has better valuation and earnings, NAMS or CGEM?

Do institutionals & insiders hold more shares of NAMS or CGEM?

Is NAMS or CGEM more profitable?

Do analysts recommend NAMS or CGEM?

Which has more risk & volatility, NAMS or CGEM?

Does the media refer more to NAMS or CGEM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGEM vs. The Competition

Cullinan Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools